The Role of Bevacizumab in the Treatment of Non-Small Cell Lung Cancer: Current Indications and Future Developments
TEST_code
|
CME Activity Information |
|
Release Date: |
October 25, 2007 |
|
Most Recent Review: |
October 25, 2007* |
|
Most Recent Update: |
October 25, 2007 |
|
Date Credit Expires: |
October 25, 2009 |
|
Time to Complete: |
1 hour |
|
Medium: |
Internet Online |
|
*Click here
to learn more about our review process. |
Instructions for Participation
- Read the following information before beginning the educational activity
and click the "Take this course" link at the bottom of the page
- Study the educational activity
- Complete the CME quiz and evaluation
- After successful completion of the CME quiz and evaluation, you will receive
the credit or participation certificate
*The CME quiz and evaluation must be completed by October 25, 2009, in order
to receive the credit or participation certificate.
Target Audience
Physicians who wish to advance their current knowledge of clinical cancer medicine
in lung cancer and are involved in providing patient care in a cancer care environment.
Learning Objectives
After completing this course, the reader should be able to:
- Describe the main clinical trials of bevacizumab combined with chemotherapy
in the treatment of advanced NSCLC.
- Describe the main clinical trials of bevacizumab combined with other targeted
therapies in the treatment of advanced NSCLC.
- Describe some ongoing trials of bevacizumab in the treatment of NSCLC and
try to define future developments of bevacizumab in this clinical setting.
Accreditation and Credit Designation
This activity has been planned and implemented in accordance
with the Essential Areas and policies of the Accreditation Council for Continuing
Medical Education (ACCME) through the joint sponsorship of the School of Medicine
of The University of North Carolina at Chapel Hill and The Oncologist.
The School of Medicine of The University of North Carolina at Chapel Hill is accredited
by the ACCME to provide continuing medical education for physicians.
The School
of Medicine of The University of North Carolina at Chapel Hill designates this
educational activity for a maximum of 1.00 AMA PRA Category 1 Credit™.
Physicians should only claim credit commensurate with the extent of their participation
in the activity.
Disclosure Policy
In compliance with the Standards of the ACCME, it is the policy of the School
of Medicine of The University of North Carolina at Chapel Hill to ensure balance,
independence, objectivity, and scientific rigor in all of its educational activities
and to include information free of commercial bias and based on the best evidence
available. All individuals in a position to influence the content of this activity
have disclosed relevant financial interests or relationships of their own, their
spouse/partner, or their worksite, with manufacturers or providers of commercial
products, services, technology, or programs; and disclosed relationships with
current non-governmental supporters of the activity. The faculty and planners
have indicated that they have no relevant commercial relationships. For a list
of the faculty and planners, please visit the Editorial Board online at http://cme.theoncologist.com/misc/edboard.shtml.
All information is submitted and reviewed and found to be scientifically rigorous,
based on the best available evidence, fair and balanced, and free of commercial
bias. All the recommendations involving clinical medicine in this CME activity
are based on evidence that is accepted within the profession of medicine as
adequate justification for their indications and contraindications in the care
of patients. All scientific research referred to, reported or used in CME in
support or justification of a patient care recommendation conforms to the generally
accepted standards of experimental design, data collection and analysis.
Any potential conflicts of interests are resolved via The Oncologist's
anonymous peer review process: http://theoncologist.alphamedpress.org/misc/ifora.shtml.
All manuscripts are reviewed by the Editorial Board with ad hoc assistance from
two or more external experts in the field. All final publication decisions are
made by the Editorial Board. The acceptance of a manuscript is based on its
originality and importance to the field as assessed by the Editors.
Author Disclosure(s)
Cesare Gridelli, M.D.
Credentials: Division of Medical Oncology, “S.G.
Moscati” Hospital, Contrada Amoretta, 83100 Avellino, Italy. Telephone:
39-0825-203573; Fax: 39-0825-203556; E-mail: cgridelli{at}libero.it.
Disclosures: The author has indicated no relevant commercial
relationships.
Paolo Maione, M.D.
Credentials: Division of Medical Oncology, “S.G.
Moscati” Hospital, Avellino, Italy.
Disclosures: The author has indicated no relevant commercial
relationships.
Antonio Rossi, M.D.
Credentials: Division of Medical Oncology, “S.G.
Moscati” Hospital, Avellino, Italy.
Disclosures: The author has indicated no relevant commercial
relationships.
Filippo De Marinis, M.D.
Credentials: I Division of Oncological Pneumology, Department
of Lung Diseases, San Camillo-Forlanini Hospitals, Roma, Italy.
Disclosures: The author has served as a consultant for Roche.
Commercial Support
Non-governmental supporters of this activity: Abraxis BioScience,
AstraZeneca, Bristol-Myers Squibb Oncology, Merck, Pfizer, and sanofi-aventis
Hardware/Software Requirements
The Oncologist CME Online supports
the following browsers: Current production versions of Opera, Safari, Firefox,
Lynx and Mozilla; Netscape 6.1 and above, and Explorer 6.0 and above. The Macintosh
version of Explorer was discontinued in June 2003, and is not supported.
Other Links
Disclaimer
Privacy statement
Correspondence
The Oncologist CME Online
c/o AlphaMed Press
318 Blackwell Street, Suite 260
Durham, North Carolina 27701
Phone: (919) 680-0011
Fax: (919) 680-4411
Email: angela.davies{at}ucdmc.ucdavis.edu
Copyright © 2008 by AlphaMed Press.